top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

274.02 -2.90 (-1.05%)
Streaming Delayed Price Updated: 9:35 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why Praxis Precision Medicines Stock Popped Today ↗
A medical breakthrough is shining a light on the biotech's promising development platform. 
Via The Motley Fool
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗
Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor. 
Via Benzinga
Praxis Precision Medicines Stock Drops After Culper Research Reveals Short Position ↗
Via Stocktwits
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗
The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies. 
Via Stocktwits
News headline image
Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗
The Data Monitoring Committee (DMC) recommended stopping the EMBOLD study ahead of schedule after the interim analysis demonstrated strong positive outcomes. 
Via Stocktwits
News headline image
Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What&#39;s Going On? ↗
Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10— what's going on? 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards' ↗
Short seller challenges Praxis' Phase 3 ulixacaltamide data, alleging major flaws that could undermine FDA approval and the company's valuation. 
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page